Characterization of a long-term mouse primary liver 3D tissue model recapitulating innate-immune responses and drug-induced liver toxicity.
Animals
Anti-Bacterial Agents
/ toxicity
Anti-Inflammatory Agents, Non-Steroidal
/ toxicity
Cells, Cultured
Chemical and Drug Induced Liver Injury
/ immunology
Hepatocytes
/ metabolism
Immunity, Innate
Liver
/ drug effects
Mice
Models, Biological
Primary Cell Culture
/ methods
Spheroids, Cellular
/ cytology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
11
2019
accepted:
22
06
2020
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Three-dimensional liver in vitro systems have recently attracted a lot of attention in drug development. These systems help to gain unprecedented insights into drug-induced liver injury (DILI), as they more closely reproduce liver biology, and as drug effects can be studied in isolated and controllable microenvironments. Many groups established human-based in vitro models but so far neglected the animal equivalent, although the availability of both models would be desirable. Animal in vitro models enable back- and forward translation of in vitro and in vivo findings, bridge the gap between rodent in vivo and human in vitro scenarios, and ultimately support the interpretation of data generated with preclinical species and humans. Since mice are often used in drug development and physiologically relevant in vitro systems are lacking, we established, for the first time, a mouse liver model that encompasses primary parenchymal and non-parenchymal cells with preserved viability and functionality over three weeks. Using our three-dimensional liver spheroids, we were able to predict the toxicity of known DILI compounds, demonstrated the interaction cascades between the different cell types and showed evidence of drug-induced steatosis and cholestasis. In summary, our mouse liver spheroids represent a valuable in vitro model that can be applied to study DILI findings, reported from mouse studies, and offers the potential to detect immune-mediated drug-induced liver toxicity.
Identifiants
pubmed: 32645073
doi: 10.1371/journal.pone.0235745
pii: PONE-D-19-31076
pmc: PMC7347206
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0235745Déclaration de conflit d'intérêts
The authors RN, ABR, and CBL are employees of F. Hoffmann-La Roche Ltd. at the Roche Innovation Center Basel, Switzerland. The authors have declared that no competing interests exist. Furthermore, this does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Expert Opin Drug Metab Toxicol. 2014 Nov;10(11):1553-68
pubmed: 25297626
Mol Pharmacol. 2010 Apr;77(4):687-94
pubmed: 20086033
Toxicol Sci. 2015 Oct;147(2):412-24
pubmed: 26160117
Exp Cell Res. 2002 Mar 10;274(1):56-67
pubmed: 11855857
Sci Rep. 2016 Feb 22;6:21373
pubmed: 26900149
Sci Rep. 2016 May 04;6:25187
pubmed: 27143246
Dev Growth Differ. 2007 Feb;49(2):171-84
pubmed: 17335438
Mol Pharmacol. 2001 Mar;59(3):627-35
pubmed: 11179459
Int J Clin Pharmacol Ther. 1995 Aug;33(8):462-4
pubmed: 8556227
Hepatology. 2012 Apr;55(4):1227-36
pubmed: 22031499
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
In Vitro. 1981 Oct;17(10):913-25
pubmed: 6273298
Drug Chem Toxicol. 2017 Oct;40(4):448-456
pubmed: 27960556
Eur J Drug Metab Pharmacokinet. 1994 Oct-Dec;19(4):311-7
pubmed: 7737232
Hepatology. 2009 Feb;49(2):578-86
pubmed: 19085959
Gastroenterology. 1996 Apr;110(4):1175-81
pubmed: 8613007
Chem Res Toxicol. 2016 Dec 19;29(12):1936-1955
pubmed: 27661221
JAMA. 2002 May 1;287(17):2215-20
pubmed: 11980521
Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94
pubmed: 17125407
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:65-82
pubmed: 29029591
J Pharm Bioallied Sci. 2014 Jan;6(1):2-9
pubmed: 24459397
J Cell Biol. 1969 Dec;43(3):506-20
pubmed: 4900611
Drug Metab Rev. 2010 Aug;42(3):446-71
pubmed: 20109035
Mol Pharmacol. 1998 Aug;54(2):273-9
pubmed: 9687568
J Cell Biol. 1985 Sep;101(3):914-23
pubmed: 2411740
Arch Toxicol. 2013 Aug;87(8):1581-93
pubmed: 23728527
Compr Physiol. 2013 Apr;3(2):785-97
pubmed: 23720329
Arch Biochem Biophys. 2003 Jun 1;414(1):91-100
pubmed: 12745259
Arch Toxicol. 2017 Aug;91(8):2849-2863
pubmed: 28612260
Drug Metab Dispos. 2016 Dec;44(12):1940-1948
pubmed: 27621203
Nat Biotechnol. 2008 Jan;26(1):120-6
pubmed: 18026090
Liver Int. 2006 Dec;26(10):1175-86
pubmed: 17105582
Drug Metab Dispos. 2001 Mar;29(3):252-7
pubmed: 11181491
Biomaterials. 2007 Dec;28(36):5487-97
pubmed: 17881050
Cells Tissues Organs. 2010;191(4):281-8
pubmed: 20051666
Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1159-74
pubmed: 19637986
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
J Antimicrob Chemother. 2006 Aug;58(2):256-65
pubmed: 16816396
Biochem Biophys Res Commun. 2000 Aug 11;274(3):707-13
pubmed: 10924340
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
J Rheumatol. 2002 Oct;29(10):2077-83
pubmed: 12375315
Curr Drug Metab. 2018;19(10):830-838
pubmed: 29788883
Toxicol Appl Pharmacol. 2006 Oct 15;216(2):293-302
pubmed: 16828827
Nat Rev Drug Discov. 2004 Mar;3(3):226-36
pubmed: 15031736
Trends Genet. 2012 Nov;28(11):560-5
pubmed: 22863032
Exp Cell Res. 2018 Feb 1;363(1):15-25
pubmed: 29291400
Xenobiotica. 2002 Jun;32(6):505-20
pubmed: 12160483
Clin Pharmacokinet. 2000 Feb;38(2):111-80
pubmed: 10709776
J Pharmacol Exp Ther. 1993 May;265(2):681-9
pubmed: 8496815
Adv Biochem Eng Biotechnol. 2007;103:309-29
pubmed: 17195468
Hepatology. 2013 Aug;58(2):799-809
pubmed: 23526496
J Pharm Sci. 2016 Feb;105(2):950-964
pubmed: 26869439
Int J Nanomedicine. 2017 May 15;12:3735-3749
pubmed: 28553111
Hepatology. 2011 Apr;53(4):1377-87
pubmed: 21480339
Semin Liver Dis. 2014 May;34(2):205-14
pubmed: 24879984
Elife. 2015 Dec 27;4:
pubmed: 26673893
AAPS J. 2008 Jun;10(2):289-99
pubmed: 18500564
J Clin Pharmacol. 2001 Jul;41(7):783-9
pubmed: 11452712
Toxicol Sci. 2008 Sep;105(1):97-105
pubmed: 18524759
Semin Liver Dis. 2001 Aug;21(3):311-35
pubmed: 11586463
Cancer Chemother Pharmacol. 1999;43(3):263-8
pubmed: 9923558
Curr Drug Metab. 2006 Aug;7(6):629-60
pubmed: 16918317
Sci Rep. 2015 Dec 03;5:17455
pubmed: 26632255
Med Clin North Am. 2008 Jul;92(4):761-94, viii
pubmed: 18570942
Toxicol Appl Pharmacol. 1998 Jan;148(1):117-25
pubmed: 9465271
Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):531-5
pubmed: 14571283
Arch Toxicol. 2013 Jan;87(1):209-13
pubmed: 23143619
Drug Metab Dispos. 2015 May;43(5):774-85
pubmed: 25739975
Biol Pharm Bull. 2012;35(4):473-80
pubmed: 22466549